Skip to main content

Advertisement

Table 2 Nanomedicine approved by FDA classified by type of carrier/material used in preparation of the formulation

From: Nano based drug delivery systems: recent developments and future prospects

Commercial name (company) Ingredient active Carrier Application Advantage Year approved
Doxil®/Caelyx™ (Janssen) Doxorubicin Liposomes Karposi’s sarcoma; Ovarian cancer; multiple myeloma Increase site-specific delivery (tumor) and decrease systemic toxicity 1995; 2005; 2008
Abelcet® (Sigma-tau) Amphotericin B lipid complex Liposomes Fungal infection Decrease toxicity 1995
DaunoXome® (Galen) Daunorubicin Liposomes Karposi’s sarcoma Increase site-specific delivery (tumor) and decrease toxicity 1996
DepoCyt© (Sigma-Tau) Cytarabine Liposomes Lymphomatous meningitis Increase site-specific delivery (tumor) and decrease toxicity 1996
AmBisome® (Gilead Sciences) Amphotericin B Liposomes Fungal and/or protozoal infections Reduced nephrotoxicity 1997
Curosurf®/Poractant alpha (Chiesei farmaceutici) Proteins SP-B and SP-C Liposomes Lung activator for stress disorder; pulmonary surfactant for respiratory distress syndrome Decrease toxicity and increased delivery for smaller volume; 1999
Visudyne® (Bausch and Lomb) Verteporfin Liposomes Ocular histoplasmosis, myopia, decreased vision Increase site-specific delivery (lesion vessels) photosensitive release 2000
DepoDur® (Pacira Pharmaceuticals) Morphine sulfate Liposomes Prolonged release Loss of pain (post-operative) 2004
Marqibo® (Onco TCS) Vincristine Liposomes Acute lymphoblastic leukemia Increase site-specific delivery (tumor) and decrease toxicity 2012
Onivyde® (Merrimack) Irinotecan Liposomes Pancreatic cancer Increase site-specific delivery (tumor) and decrease toxicity 2015
Adagen® (Sigma-Tau Pharmaceuticals) Pegademase bovine PEGylated adenosine deaminase enzyme Immunodeficiency disease Improve circulation time in body and decrease immunogenicity 1990
Oncaspar® (Enzon Pharmaceuticals) l-Asparaginase PEGylated l-asparaginase Acute lymphoblastic leukemia Improved protein stability due PEGylation 1994
Copaxone® (Teva) Glatopa l-Glutamate, l-alanine, l-lysine and l-tyrosine random copolymer Multiple sclerosis Regulation of clearance and polymer with controlled molecular weight 1996
Renagel® (Sanofi) Sevelamer hydrochloride or sevelamer carbonate Poly(allylamine hydrochloride) Chronic renal diseases Increase site-specific delivery and increase in circulation time in body 2000
PegIntron® (Merck) Interferon-alpha (IFN-α2b) PEGylated IFN-α2b protein Hepatitis C Improved protein stability due PEGylation 2001
Pegasys® (Genentech) Interferon-alpha (IFN-α2a) PEGylated IFN-α2a protein Hepatitis B and C Improved protein stability due PEGylation 2002
Eligard® (Tolmar) Leuprolide acetate Polymer (PLGH (poly(dl-lactide-co glycolide) Prostate cancer Prolonged drug delivery and circulation time in body 2002
Neulasta® (Amgen) PEG-filgrastim PEGylated granulocyte colony-stimulating factor (GCSF) protein Neutropenia induced by chemotherapy Improved protein stability due PEGylation 2002
Somavert® (Pfizer) PEG-visomant PEGylated HGH receptor antagonist Acromegaly Improved protein stability due PEGylation 2003
Macugen® (Bausch & Lomb) PEG-aptanib PEGylated anti vascular endothelial growth factor aptamer Macular degeneration; neovascular age-related (decreased vision) Improved stability due PEGylation 2004
Mircera® (Hoffman-La Roche) Methoxy polyethylene glycol-epoetin beta Chemically synthesized erythropoiesis-stimulating agent Anemia associated with renal failure due to diseases Improved stability due PEGylation 2007
Cimzia® (UCB) Certolizumab pegol PEGylated antibody fragment (Certolizumab) Crohn’s disease; rheumatoid arthritis; psoriatic arthritis and ankylosing spondylitis Increase stability and circulation time in body 2008; 2009; 2013; 2013
Krystexxa® (Horizon) PEG-loticase PEGylated porcine-like uricase Chronic gout Improved protein stability due to PEGylation 2010
Plegridy® (Biogen) Interferon-beta (IFN-β1a) PEGylated IFN-β1a protein Multiple sclerosis Improved protein stability due to PEGylation 2015
ADYNOVATE (Baxalta) Factor VIII PEGylated factor VIII Hemophilia Improved protein stability due to PEGylation 2015
Rapamune® (Wyeth Pharmaceuticals) Sirolimus Nanocrystals Immunosuppressant Increased bioavailability 2000
Megace ES® (Par Pharmaceuticals) Megestrol acetate Nanocrystals Anti-anorexic Reduced posology 2001
Avinza® (Pfizer) Morphine sulfate Nanocrystals Mental stimulant Prolonged release and increased bioavailability 2002/2015
Ritalin LA® (Novartis) Methylphenidate HCl Nanocrystals Mental stimulant Increased drug loading and bioavailability 2002
Zanaflex® (Acorda) Tizanidine HCl Nanocrystals Muscle relaxant Increased bioavailability and decreased posology 2002
Emend® (Merck) Aprepitant Nanocrystals Antiemetic drug Increased absorption and bioavailability 2003
Vitoss® (Stryker) Calcium phosphate Nanocrystals Bone substitute Mimics bone structure by cell adhesion and growth 2003
OsSatura® (IsoTis Orthobiologics) Hydroxyapatite Nanocrystals Bone substitute Mimics bone structure by cell adhesion and growth 2003
Ostim® (Heraseus Kulzer) Hydroxyapatite Nanocrystals Bone substitute Mimics bone structure by cell adhesion and growth 2004
Tricor® (Lupin Atlantis) Fenofibrate Nanocrystals Hyperlipidemia Increased bioavailability 2004
Focalin XR® (Novartis) Dexmethylphenidate HCl Nanocrystals Mental stimulant Increased bioavailability 2005
NanOss® (Rti Surgical) Hydroxypatite Nanocrystals Bone substitute Mimics bone structure by cell adhesion and growth 2005
EquivaBone® (Zimmer Biomet) Hydroxypatite Nanocrystals Bone substitute Mimics bone structure 2009
Invega® Sustenna® (Janssen Pharms) Paliperidone palmitate Nanocrystals Schizophrenia schizoaffective disorder Decreased release of poor water-soluble drugs 2009/2014
Ryanodex® (Eagle Pharmaceuticals) Dantrolene sodium Nanocrystals Malignant hypothermia Allows higher administration at higher doses 2014
Estrasorb™ (Novavax) Estradiol Micelles Menopause hormone therapy Sustained release 2003
Abraxane® (Celgene) Paclitaxel (ABI-007) Albumin-bound paclitaxel nanoparticles Breast cancer; non-small cell lung cancer and pancreatic cancer Increase site-specific delivery (tumor) and solubility 2005;2012;2013
INFeD® (Sanofi Avertis) Iron Iron dextran (low MW) Chronic kidney failure with iron deficiency Increased dose capacity 1957
DexIron®/Dexferrum® (Sanofi Avertis) Iron Iron dextran (high MW) Chronic kidney failure with iron deficiency Increased dose capacity 1957
Feridex®/Endorem® (AMAG pharmaceuticals) Superparamagnetic iron oxide nanoparticles (SPION) SPION coated with dextran Imaging material Superparamagnetic character 1996/2008
Ferrlecit® (Sanofi Avertis) Sodium ferric Sodium ferric gluconate Chronic kidney failure with iron deficiency Increased dose capacity 1999
Venofer® (Luitpold Pharmaceuticals) Iron oxide Iron sucrose Chronic kidney failure with iron deficiency Increased dose capacity 2000
GastroMARK™; umirem® (AMAG pharmaceuticals) Superparamagnetic iron oxide nanoparticles (SPION) SPION coated with silicone Imaging material Superparamagnetic character 2001/2009
Feraheme™ (AMAG pharmaceuticals) Ferumoxytol-ultrasmall superparamagnetic iron oxide nanopartilces (SPION) Ferumoxytol SPION with polyglucose sorbitol carboxymethylether Chronic kidney failure with iron deficiency Prolonged steady release and decreased number of doses 2009
Nanotherm® (MagForce) Iron oxide Aminosilane-coated Iron nanoparticles Brain tumor Thermotherapy for destroy tumor cells or sensitized for additional therapies  2010